Zhang Jing, Qiu Xiaoguang, Feng Jin, Liu Yanwei
Department of Radiation Oncology, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China.
Chin Neurosurg J. 2024 Jul 24;10(1):24. doi: 10.1186/s41016-024-00375-2.
High-grade gliomas (HGGs) have a rapid relapse and short survival. Studies have identified many clinical characteristics and biomarkers associated with progression-free survival (PFS) and over-survival (OS). However, there has not yet a comprehensive study on survival after the first progression (SAP).
From CGGA and TCGA, 319 and 308 HGGs were confirmed as the first progression. The data on clinical characteristics and biomarkers were analyzed in accordance with OS, PFS, and SAP.
Analysis of 319 patients from CGGA, significant predictors of improved OS/PFS/SAP were WHO grade, MGMT promoter methylation, and Ki-67 expression in univariate analysis. Further multivariate analysis showed MGMT promoter methylation and Ki-67 expression were independent predictors. However, an analysis of 308 patients from TCGA found MGMT promoter methylation is the only prognostic marker. A longer SAP was observed in patients with methylated MGMT promoter after standard chemoradiotherapy. In our data, HGGs could be divided into low, intermediate, and high-risk groups for SAP by MGMT methylation and Ki-67 expression.
Patients with MGMT promoter methylation have a prolonger SAP after standard chemoradiotherapy. HGGs could be divided into low, intermediate, and high-risk groups for SAP according to MGMT status and Ki-67 expression.
高级别胶质瘤（HGGs）复发迅速且生存期短。研究已确定了许多与无进展生存期（PFS）和总生存期（OS）相关的临床特征和生物标志物。然而，尚未有关于首次进展后生存期（SAP）的全面研究。
从CGGA和TCGA中，分别有319例和308例HGGs被确认为首次进展。根据OS、PFS和SAP对临床特征和生物标志物数据进行分析。
对CGGA的319例患者进行分析，单因素分析中，OS/PFS/SAP改善的显著预测因素为世界卫生组织（WHO）分级、MGMT启动子甲基化和Ki-67表达。进一步的多因素分析显示，MGMT启动子甲基化和Ki-67表达是独立预测因素。然而，对TCGA的308例患者进行分析发现，MGMT启动子甲基化是唯一的预后标志物。标准放化疗后，MGMT启动子甲基化的患者观察到更长的SAP。在我们的数据中，HGGs可根据MGMT甲基化和Ki-67表达分为SAP的低、中、高风险组。
MGMT启动子甲基化的患者在标准放化疗后有更长的SAP。HGGs可根据MGMT状态和Ki-67表达分为SAP的低、中、高风险组。
